Taiho Oncology, Inc.
Gregory R. Lynch has a diverse work experience in the pharmaceutical and market research industry. Gregory R. is currently working as the Director of Business Insights & Analytics at Taiho Oncology, Inc. Prior to this role, they held positions at Merck as the Associate Director/Team Lead for KEYTRUDA+LENVIMA Insights, Teva Pharmaceuticals as the Associate Director/Team Lead for Oncology Insights, and Shire as the Associate Director/Insights Lead for the ADHD drug VYVANSE. Gregory also worked at Cephalon, Teva Pharmaceuticals, Strategic Business Research, Inc. (SBR), Genactis, Inc., and The Unland Hayes Group in various market research and managerial roles.
Gregory R. Lynch completed their Bachelor of Arts degree at Washington and Lee University from 1991 to 1995. Gregory R. pursued a double major in Journalism and History during this time. Later on, from 2002 to 2008, they attended the Erivan K. Haub School of Business at Saint Joseph's University, where they obtained their Master of Business Administration (MBA) degree, with a concentration in Marketing.
This person is not in any offices
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com